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Cardiovascular disease (CVD) events are the main causes of death in end-stage renal disease (ESRD) patients on dialysis. The number
and severity of CVD events remain inappropriate and difficult to explain by considering only the classic CVD risk factors. Our aimwas
to clarify the changes and the relationship of lipoprotein subfractions with other CVD risk factors, namely, body mass index (BMI)
and adipokines, inflammation and low-density lipoprotein (LDL) oxidation, and the burden of the most prevalent comorbidities,
diabetes mellitus (DM) and hypertension (HT). We studied 194 ESRD patients on dialysis and 22 controls; lipid profile, including
lipoprotein subpopulations and oxidized LDL (oxLDL), C-reactive protein (CRP), adiponectin, leptin, and paraoxonase 1 activity
were evaluated. Compared to controls, patients presented significantly lower levels of cholesterol, high-density lipoprotein
cholesterol (HDLc), LDLc, oxLDL, and intermediate and small HDL and higher triglycerides, CRP, adiponectin, large HDL,
very-low-density lipoprotein (VLDL), and intermediate-density lipoprotein- (IDL) B. Adiponectin levels correlated positively with
large HDL and negatively with intermediate and small HDL, oxLDL/LDLc, and BMI; patients with DM (n = 17) and with DM+HT
(n = 70), as compared to patients without DM or HT (n = 69) or only with HT (n = 38), presented significantly higher oxLDL,
oxLDL/LDLc, and leptin and lower adiponectin. Obese patients (n = 45), as compared to normoponderal patients (n = 81), showed
lower HDLc, adiponectin, and large HDL and significantly higher leptin, VLDL, and intermediate and small HDL. In ESRD, the
higher adiponectin seems to favor atheroprotective HDL modifications and protect LDL particles from oxidative atherogenic
changes. However, in diabetic and obese patients, adiponectin presents the lowest values, oxLDL/LDLc present the highest ones, and
the HDL profile is the more atherogenic. Our data suggest that the coexistence of DM and adiposity in ESRD patients on dialysis
contributes to a higher CVD risk, as showed by their lipid and adipokine profiles.
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1. Introduction
End-stage renal disease (ESRD) patients present high mor-
bidity and mortality rates, and the main causes of death
are cardiovascular disease- (CVD) related events [1, 2]. Dia-
betes mellitus (DM) and hypertension (HT) are the most
common causes for renal failure and are known as risk fac-
tors for CVD events.
ESRD patients on hemodialysis (HD) frequently present
normal or decreased values of total cholesterol (TC) and
low-density lipoprotein cholesterol (LDLc), decreased
high-density lipoprotein cholesterol (HDLc), and increased
triglyceride (TG) values [3]. A high prevalence of some tradi-
tional CV risk factors is common, though the number and
severity of CVD events remain inappropriate and hard to
explain when considering only the classic CVD risk factors.
A study by our group showed that TG and C-reactive protein
(CRP) levels, as well as the type of vascular access, were inde-
pendent risk factors for all-cause mortality in ESRD patients
onHD [4]. It appears that other factors may underlie the inap-
propriately high CVD events in ESRD patients, namely, oxida-
tive stress/inflammatory-related changes, adipocyte-related
cytokines, and altered functionality in lipoproteins.
LDL and HDL are a heterogeneous population of parti-
cles with different atherogenic or atheroprotective properties.
It has been hypothesized that lipoprotein’s quality (size, com-
position, and functionality) may be more important than
their total circulating levels, as a CVD risk factor. In fact,
smaller and denser LDL subpopulations are more athero-
genic than larger LDL subpopulations [5, 6]. In addition, a
reduction in HDL size has been also associated with less
functionality [7–9]; however, this issue is not consensual
[6]. A study of incident diabetic patients showed lower per-
centages of large HDL particles, higher percentages of small
LDL subfractions, and a reduction in LDL size [10].
A large number of studies evaluated lipid risk profile in
ESRD; however, the studies concerning the lipoprotein sub-
fractions, evaluated by high-resolution electrophoresis on
polyacrylamide gel tubes, are sparse, with some controversial
results and involving a small number of patients [11–13].
These studies reported that ESRD patients, as compared to
controls, present increased large HDL particles and decreased
small HDL particles [11–13], while data on LDL subfractions
is controversial. Moreover, the interplay between lipoprotein
quality, oxidative stress, inflammation, and adipokines was
not addressed in these studies.
Oxidation of LDL (oxLDL) is a triggering factor for initi-
ation and progression of atherosclerosis. The oxLDL/LDL
ratio, used to measure the value of LDL oxidation within
LDL particles, seems to be raised in ESRD patients, showing
a lower antioxidant protection for LDL particles [14]. ESRD
patients on dialysis also present reduced paraoxonase 1
(PON1) activity that has been associated with inflammation,
longer time on dialysis, and high recombinant human eryth-
ropoietin doses [14].
Obesity is a CVD risk factor and a risk factor for
development of chronic kidney disease (CKD) and diabe-
tes. Adiponectin, mainly synthesized by adipocytes, with
anti-inflammatory, insulin-sensitizing, and antiatherogenic
properties, is increased in ESRD patients and seems to
present a negative correlation with body mass index
(BMI) in these patients [15, 16]. Hyperleptinemia has been
associated with inflammation, insulin resistance, and pro-
tein energy wasting and with progression of CKD [17].
Considering the few data on lipoprotein subpopulations
in ESRD and, particularly, on their potential implications
on morbidity and mortality, the aim of this work was to fur-
ther clarify the changes in lipoprotein profiles and, particu-
larly, the relationship with other CVD risk factors, namely,
BMI and adipokine levels, inflammation, and LDL oxidation,
and with the burden of the most prevalent comorbidities in
ESRD patients, diabetes and hypertension.
2. Material and Methods
2.1. Subjects. This study included patients from five dialysis
clinics in the Northern Region of Portugal; the Commit-
tee on Ethics, from the Faculty of Pharmacy, Porto Univer-
sity, approved the study protocol. Patients and controls
participated in the study after signing an informed and writ-
ten consent, respecting their privacy rights. Patients with
malignancy, autoimmune disease, and inflammatory or
infectious diseases and with increased alanine transaminase
and/or aspartate transaminase levels were excluded.
The study included 194 ESRD patients under chronic
dialysis (28 on HD and 166 under online hemodiafiltration),
for more than 90 days. Therapeutic dialysis was performed 3
times per week, for 3-5 hours, and patients were on dialysis
treatment for a median period of 4.09 (1.74–7.60) years. Dial-
ysis clearance of urea was expressed as Kt/V . The main
causes of renal disease were diabetic nephropathy (n = 79),
hypertensive nephrosclerosis (n = 32), chronic glomerulone-
phritis (n = 11), polycystic kidney disease (n = 8), other dis-
eases (n = 26), and uncertain etiology (n = 38). Concerning
vascular access, 26 patients used central venous catheter,
158 used an arteriovenous fistula, and 10 patients used an
arteriovenous graft. Diabetes was established by current
guidelines [18] and/or by the use of insulin or oral hypogly-
cemic drugs. Hypertension was defined by current guidelines
[19] or by the use of hypertensive agents.
A group of 22 healthy volunteers was selected as control,
based on normal hematological and biochemical values, and
no history of kidney, inflammatory diseases or dyslipidemia.
2.2. Collection and Preparation of Blood Samples. Blood was
collected immediately before dialysis procedure, by vene-
puncture, into tubes with and without anticoagulant (ethyl-
enediaminetetraacetic acid), in order to obtain plasma and
serum, respectively. Samples were processed within 2 hours
of collection; aliquots of plasma and serum were prepared
and immediately stored at -80°C until assayed.
2.3. Analytical Assays. Lipid profile was evaluated by routine
procedures, using an autoanalyser (Cobas Integra 400 Plus,
Roche Diagnostics, Basel, Switzerland) and commercially
available kits; TC, TG, HDLc, and LDLc concentrations were
determined by enzymatic colorimetric tests (Roche Diagnos-
tics, Basel, Switzerland).
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HDL and LDL subpopulations were separated and
quantified using a Lipoprint® kit from Quantimetrix Corp.
(Redondo Beach, CA, USA). This analysis involves a poly-
acrylamide gel electrophoresis followed by a complete data
acquisition and quantification of lipoprotein subpopulations,
using the Lipoprint System.
HDL is separated into 10 subfractions that are classified
as large HDL particles (1-3 subfractions), intermediate
HDL particles (4-7 subfractions), and small HDL particles
(8-10 subfractions).
LDL particles are divided into 7 subpopulations, the LDL1
and LDL2 subpopulations corresponding to larger LDL parti-
cles and LDL3 to LDL7 subfractions corresponding to small
LDL particles. Besides the LDL subfractions, the LDL Lipo-
print profile also includes one band ofVLDL, 3midbands cor-
responding to intermediate-density lipoprotein (IDL), and
one HDL band. The mean LDL particle size is determined.
Circulating levels of oxLDL, adiponectin, and leptin were
evaluated by enzyme immunoassays (Oxidized LDL ELISA,
Mercodia, Uppsala, Sweden, and human total adiponectin
and human leptin, R&D Systems Inc., Minneapolis, USA,
respectively); the oxLDL/LDLc ratio was calculated to assess
the value of LDL oxidation within LDL particles. CRP values
were measured by immunoturbidimetry (High-Sensitivity
CRP (latex), Roche Diagnostics, Basel, Switzerland). PON1
activity was assessed spectrophotometrically and expressed
in nmol of p-nitrophenol/ml/min. PON1 activity was evalu-
ated by adding serum to 1ml Tris/HCl buffer (100mmol/l,
pH8.0) containing 2mmol/l CaCl2 and 5.5mmol/l paraoxon
(O,O-diethyl-O-p-nitrophenylphosphate; Sigma Chemical
Co.). The rate of generation of p-nitrophenol was determined
at 412nm, 37°C, via the use of a continuously recording
spectrophotometer.
2.4. Statistical Analysis. Statistical analysis was performed
using the Statistical Package for Social Sciences (SPSS, version
23.0, Chicago, IL, USA) for Windows. Kolmogorov-
Smirnovanalysis was used to determine if data presented
a normal distribution. Parameters presenting a non-
Gaussian distribution are presented as median (interquar-
tile range); for those with Gaussian distribution, results
are presented asmean ± standard deviation. For comparisons
between controls and patients, we used, for continuous vari-
ables, the Mann-Whitney U test and the unpaired Student t
-test, in accordance with the Gaussian distribution of the var-
iables; for categorical variables, chi-squared test and Fisher’s
exact test were employed. To compare the groups in terms
of comorbidities, we used one-way ANOVA supplemented
with Tukey post hoc test (for variables presenting a normal
distribution). Adjustment for confounding factors (e.g., age,
BMI, diabetes) was performed using analysis of covariance
(ANCOVA; variable data respected a normal distribution).
Data presenting a non-Gaussian distribution were trans-
formed to data with normal distribution, by using the
method described by Templeton [20]. Spearman’s rank cor-
relation coefficient was performed to evaluate relationships
between sets of data. To evaluate the contribution of the dif-
ferent variables to adiponectin levels, a multiple regression
analysis was performed, using stepwise selection (all variable
data included in the regression analysis respected a normal
distribution). A P value lower than 0.05 was considered as
statistically significant.
3. Results
Controls and patients did not present significant differences
in what concerns gender, weight, height, and BMI; clinical
data for patients is showed in Table 1. Patients, as compared
to controls, presented significantly lower values of TC, HDLc,
LDLc, oxLDL, and LDLc/HDLc and significantly higher TG,
CRP, and adiponectin levels (Table 1). Concerning HDL sub-
fractions, patients presented higher percentage of large HDL
and lower percentages of intermediate and small HDL. As
compared to controls, ESRD patients also presented signifi-
cantly higher VLDL and MID-B (%) and lower % of larger
LDL (LDL 1 and LDL 2). Differences persisted significant
after statistical adjustment for age.
Adiponectin correlated positively with large HDL
(Figure 1(a)) and negatively with BMI (Figure 1(b)), oxLDL
(r = −0 306, P < 0 001), and oxLDL/LDLc (Figure 1(c)), as
well as with intermediate HDL (r = −0 374, P < 0 001), small
HDL (r = −0 447, P < 0 001), VLDL (r = −0 388, P < 0 001),
and leptin (r = −0 390, P < 0 001).
Leptin correlated inversely with large HDL (r = −0 286,
P < 0 001) and positively with intermediate HDL (r = 0 212,
P = 0 003), small HDL (r = 0 271, P < 0 001), VLDL (r =
0 209, P = 0 003), and BMI (r = 0 579, P < 0 001).
OxLDL and oxLDL/LDLc correlated significantly
and negatively with large HDL (r = −0 401, P < 0 001; r =
−0 240, P = 0 001, respectively) and positively with interme-
diate HDL (r = 0 253, P < 0 001; r = 0 143, P = 0 007, respec-
tively), small HDL (r = 0 390, P < 0 001; r = 0 232, P = 0 001,
respectively), VLDL (r = 0 281, P < 0 001; r = 0 196, P =
0 006, respectively), and BMI (r = 0 186, P = 0 009; r =
0 252, P < 0 001, respectively). OxLDL also correlated with
LDL size (r = −0 251, P < 0 001), CRP (r = 0 143, P = 0 047),
and leptin (r = 0 271, P < 0 001).
BMI correlated with large HDL (r = −0 379, P < 0 001),
intermediate HDL (r = 0 276, P < 0 001), small HDL
(r = 0 346, P < 0 001), and PON1/HDLc (r = 0 295, P < 0 001).
In multiple linear regression, after transformation to var-
iables with normal distribution, large HDL (β = 0 322; P <
0 001) and oxLDL/LDLc (β = −0 288; P = 0 001), as well as
BMI (β = −0 308; P < 0 001), remained significantly associ-
ated with adiponectin.
Concerning the most frequent comorbidities in ESRD
patients, diabetes and hypertension, we analyzed our data
according to the association with those comorbidities. We
found that 17 patients presented only DM, 38 presented only
HT, 70 presented simultaneously DM and HT (DM+HT),
and 69 patients did not present DM nor HT. Concerning
the use of statins, 58.8% in the DM group, 44.7% in the HT
group, 68.6% in the DM+HT group, and 43.5% of the
patients that did not present DM or HT were on statin ther-
apy. The four groups did not differ significantly in age and
gender but differed in BMI, which was higher in DM and
DM+HT groups (Table 2). Patients with DM and with DM
+HT, as compared to patients without DM and HT or
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patients with only HT, presented higher values of oxLDL,
oxLDL/LDLc, and leptin and lower adiponectin (Figure 2).
Patients with DM, as compared to patients without DM
and HT, after statistical adjustment for BMI, presented
higher intermediate HDL; the significance for leptin was
lost. Patients with DM+HT, as compared to the group
Table 1: Demographic and clinical data, lipid profile, oxidized low-density lipoprotein (oxLDL), paraoxonase (PON) 1 activity, C-reactive
protein (CRP), adipokines, and fractions and subfractions of lipoproteins, for the control group and end-stage renal disease (ESRD)
patients under chronic dialysis.
Controls (n = 22) ESRD patients (n = 194) P value
Demographic and clinical data
Age (years) 56.9 (52.3–59.8) 71.3 (60.0–79.6) <0.001
Gender 14 F/8 M 87 F/107 M 0.095
Weight (kg) 65.5 (58.8–80.3) 68.7 (58.5–78.7) 0.983
Height (cm) 170 (157–175) 162 (157–170) 0.078
BMI (kg/m2) 24 3 ± 3 4 25 8 ± 4 7 0.073
Systolic blood pressure (mmHg) 123 ± 10 137 ± 22 <0.001
Diastolic blood pressure (mmHg) 80 ± 7 62 ± 13 <0.001
Dialysis length (years) — 4.09 (1.74–7.60) —
URR (%) — 79.0 (75.8–83.0) —
Kt/V — 1 82 ± 0 31 —
Ultrafiltration volume (ml) — 2371 ± 919 —
Biochemical data
TC (mg/dl) 202 ± 23 160 ± 39 <0.001
HDLc (mg/dl) 52.6 (44.7–65.4) 46.0 (39.2–56.6) 0.022
LDLc (mg/dl) 122 (104–138) 79 (63–103) <0.001
TG (mg/dl) 90.0 (71.3–107.5) 130.5 (97.5–178.5) <0.001
TC/HDLc 3.70 (3.03–4.66) 3.31 (2.71–4.10) 0.119
LDLc/HDLc 2.27 (1.58–2.87) 1.73 (1.28–2.30) 0.014
oxLDL (U/l) 67.5 (55.5–73.5) 46.5 (36.5–60.0) <0.001
oxLDL/LDLc (U/mg) 0.055 (0.049–0.064) 0.059 (0.050–0.069) 0.310
PON1 (nmol of p-nitrophenol/ml/min) 413 (386–467) 405 (361–473) 0.579
PON1/HDLc 8.43 (6.23–9.94) 9.05 (6.99–11.15) 0.107
CRP (mg/dl) 0.10 (0.04–0.21) 0.37 (0.15–0.72) <0.001
Adiponectin (μg/ml) 5.75 (3.02–8.35) 12.28 (7.86–19.25) <0.001
Leptin (ng/ml) 9.3 (4.9–20.6) 14.0 (5.1–41.5) 0.144
Lipoprotein fractions/subfractions
VLDL (%) 14 3 ± 3 0 18 7 ± 4 0 <0.001
MID-C (%) 15 1 ± 2 4 16 1 ± 2 3 0.054
MID-B (%) 6.6 (5.9–7.7) 7.8 (6.6–9.0) 0.004
MID-A (%) 6.3 (5.6–8.5) 6.8 (5.4–8.4) 0.941
LDL 1 (%) 18.3 (16.3–20.0) 13.0 (10.7–15.4) <0.001
LDL 2 (%) 9.9 (7.4–13.0) 8.1 (5.6–10.9) 0.036
LDL 3-7 (%) 0.7 (0.0–1.1) 0.7 (0.0–1.7) 0.789
HDL (%) 27.0 (24.0–31.2) 26.8 (23.2–30.2) 0.793
LDL size 271 (270–272) 270 (268–272) 0.265
HDL subfractions
Large HDL (%) 24.7 (22.3–31.6) 37.2 (28.3–44.9) <0.001
Intermediate HDL (%) 48.8 (45.9–50.6) 45.6 (41.2–49.8) 0.013
Small HDL (%) 24.9 (17.5–29.5) 17.4 (12.6–22.7) 0.001
F: female; M: male; BMI: body mass index; URR: urea reduction ratio; TC: total cholesterol; HDLc: high-density lipoprotein cholesterol; TG: triglycerides;
VLDL: very-low-density lipoprotein; MID: midbands (these comprise intermediate-density lipoprotein (IDL)); LDL 3–7 corresponds to small LDL
subfractions. Values are presented as median (interquartile range) or as mean ± standard deviation (SD).
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without DM or HT, presented, after statistical adjustment for
BMI, higher oxLDL/LDLc, adiponectin, leptin, and MID-A
percentage and lower TC, HDLc, LDLc, and CRP. Patients
with HT, as compared to those with only DM, revealed
higher HDLc and large HDL and lower TG, PON1/HDLc,
and intermediate HDL. Patients with DM+HT, as com-
pared to the group of patients with only HT, presented, after
statistical adjustment for BMI, higher values of TG, oxLDL,
oxLDL/LDLc, and leptin and lower CRP and adiponectin
(Table 2). There were no statistically significant differences
for the studied variables between patients with HT and
patients without DM or HT.
We also analyzed our data according to BMI categories
(Table 3). The groups did not differ significantly in what con-
cerns age, gender, and number of cases of HT but differed in
the number of cases of diabetes; the underweight (BMI < 18 5
kg/m2) patients were not diabetic; the normal weight (BMI
18.5-24.9 kg/m2) group had lower number of cases of diabe-
tes (33%) than the overweight (BMI 25-29.9 kg/m2) and
obese (BMI ≥ 30 kg/m2) groups (43% and 58%, respectively).
Regarding statin therapy, 50.0% of underweight patients,
40.7% of normoponderal patients, 66.7% of overweight
patients, and 62.2% of obese patients were on statin therapy.
In the underweight group, the number of patients was
small (n = 8), compromising statistical evaluation; therefore,
we did not analyze data from this group.
Overweight (n = 60) and obese (n = 45) patients, as
compared to normoponderal patients (n = 81), showed sig-
nificantly lower HDLc, adiponectin, and % of large HDL
and significantly higher TG, oxLDL/LDLc, PON1/HDLc,
leptin, % of VLDL, and small HDL. Obese patients also pre-
sented significantly higher % of intermediate HDL, oxLDL,
TC/HDLc, and LDLc/HDLc than normal weight patients.
After statistical adjustment for diabetes, the statistical dif-
ferences observed for the overweight group were lost; in
the obese group, differences found for HDLc, PON1/HDLc,
adiponectin, leptin, VLDL, large HDL, intermediate HDL,
and small HDL persisted. Obese, as compared to overweight
patients, presented higher values of leptin and % of small
HDL and lower large HDL; after statistical adjustment for
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Figure 1: Correlations observed between adiponectin and (a) large high-density lipoprotein (HDL; r = 0 509, P < 0 001), (b) body mass index
(BMI; r = −0 431, P < 0 001), and (c) oxidized low-density lipoprotein (oxLDL)/LDLc ratio (r = −0 434, P < 0 001) in end-stage renal disease
patients on chronic dialysis.
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diabetes, only the differences for leptin remained significant
(Table 3).
4. Discussion
In this work, we studied in ESRD patients the modifications
in LDL and HDL profiles and their relationship with BMI,
adipokine levels, inflammation, and LDL oxidation and with
the coexistence of DM and HT, the most prevalent comor-
bidities in these patients.
We found that ESRD patients on HD presented some
significant risk changes in lipid profile, namely, decreased
HDLc and increased TG values, alongside with protective
changes, such as decreased TC and LDLc, as compared
to the control group.
An increase in small HDL subpopulations was found in
patients with coronary artery disease (CAD) [9]. Patients
with acute coronary syndrome (ACS) and with stable CAD
showed dysfunctional HDL subfractions that have distinct
composition and diminished anti-inflammatory potential,
especially for HDL3 in ACS, which can be used to discrimi-
nate between these two conditions [21]. In a Chinese cohort,
it was found that large HDL subpopulation correlated nega-
tively to very early CAD [22]. Higher values of small LDL
particles and lower values of large HDL particles, as well as
a reduction in LDL size, were reported in incident diabetes
[10]. Decreased large HDL particles and increased small
HDL particles were found in patients with hypertension
[23]. However, as previously mentioned, it is still a matter
of debate which subfraction of HDL is more atheroprotective
[6], with reports referring a positive association between
HDL3 and protection from CAD [24], in opposition to the
above-referred reports in the opposite direction. In spite of
the lower circulating levels of HDL, the study of its subfrac-
tions showed a less atherogenic profile in patients than in
controls, presenting significantly higher percentage of large
HDL particles and lower intermediate and small HDL sub-
fractions. These results are in accordance with published data
[11–13]. Nevertheless, it has been reported that the content
of HDL in triglycerides and phospholipids appears to be
Table 2: Body mass index (BMI), lipid profile, paraoxonase (PON) 1 activity, C-reactive protein (CRP), and fractions and subfractions of
lipoproteins, for end-stage renal disease (ESRD) patients on chronic dialysis, according to the more prevalent comorbidities, diabetes
mellitus (DM) and hypertension (HT).
noDM/HT (n = 69) HT (n = 38) DM (n = 17) DM+HT (n = 70)
BMI (kg/m2) 24 1 ± 4 3 25 0 ± 5 4 28.0aa ± 4.7 27.4aaa ± 4.0b
Biochemical data
TC (mg/dl) 170 ± 39 164 ± 37 156 ± 33 149aa ± 38b,∗
HDLc (mg/dl) 50.6 (43.8–59.6) 46.1 (40.0–61.9) 39.7aa,∗ (34.8–47.8)b 43.0aa∗ (36.9–53.8)∗
LDLc (mg/dl) 88 (68–107) 77 (65–112) 82 (64–105) a72 (57–91)
TG (mg/dl) 121.0 (96–165.5) 115.0 (85.0–141.5) 189.0a,∗ (116.0–258.0)bb 141.0a,∗ (98.9–195.0)b
TC/HDLc 3.37 (2.71–4.04) 3.40 (2.44–4.23) 3.38 (3.00–4.98) 3.15 (2.74–4.04)
LDLc/HDLc 1.80 (1.28–2.27) 1.83 (1.06–2.41) 1.79 (1.65–3.10) 1.67 (1.29–2.16)
PON1 (nmol of p-nitrophenol/ml/min) 410 (368–476) 384 (350–472) 431 (355–480) 398 (362–466)
PON1/HDLc 8.74 (6.52–10.13) 8.45 (6.32–10.92) 10.38a,∗ (9.00–13.86)b 9.73a,∗ (7.41–11.74)
CRP (mg/dl) 0.43 (0.18–0.74) 0.46 (0.19–0.99) 0.53 (0.24–0.93) 0.24a (0.11–0.48)b
Lipoprotein fractions/subfractions
VLDL (%) 18 1 ± 3 7 17 8 ± 4 0 20 1 ± 4 2 19 4 ± 4 1
MID-C (%) 16 0 ± 2 0 16 0 ± 2 5 16 7 ± 2 1 16 2 ± 2 4
MID-B (%) 7.8 (6.8–8.7) 7.2 (6.1–8.3) 7.3 (6.4–9.4) 8.3 (6.8 -10.1)b
MID-A (%) 6.5 (5.1–7.6) 6.8 (5.9–8.2) 5.7 (4.6–8.8) 7.4 (5.6–8.9)a
LDL 1 (%) 12.8 (10.7–15.0) 13.5 (10.6–15.9) 12.4 (9.8–14.0) 13.3 (11.3–15.9)
LDL 2 (%) 8.3 (6.2–11.6) 8.2 (4.4–10.5) 7.8 (6.2–11.2) 8.0 (5.1–9.9)
LDL 3-7 (%) 0.7 (0.0–1.6) 0.4 (0.0–1.7) 0.9 (0.0–4.6) 0.8 (0.0–1.6)
HDL (%) 27.6 (24.3–30.8) 28.4 (22.6–33.8) 25.3a (22.2–27.0) 24.8aa (21.9–29.4)b,∗
LDL size 270 (268–272) 270 (268–273) 271 (264–272) 270 (268–272)
HDL subfractions
Large HDL (%) 40.6 (29.4–46.2) 39.6 (29.3–48.7) 35.0a,∗ (21.1–39.6)b 33.2aa,∗ (26.0–41.6)b,∗
Intermediate HDL (%) 45.0 (41.2-48.6) 43.7 (39.4–48.9) 50.0a (41.9–51.0)b 46.4 (43.1–50.4)
Small HDL (%) 15.0 (11.1–21.6) 16.4 (12.0–21.3) 21.9 (12.8–21.7) 19.1a,∗ (13.9–24.0)
TC: total cholesterol; HDLc: high-density lipoprotein cholesterol; LDLc: low-density lipoprotein cholesterol; TG: triglycerides; VLDL: very-low-density
lipoprotein; MID: midbands (these comprise intermediate-density lipoprotein (IDL)); LDL 3–7 corresponds to small LDL subfractions. Values are presented
as median (interquartile range) or as mean ± standard deviation (SD); aP < 0 05, aaP < 0 01, and aaaP < 0 001 vs. ESRD patients without DM or HT
(noDM/HT); bP < 0 05, bbP < 0 01, and bbbP < 0 001 vs. ESRD patients with HT; ∗loss of significance after statistical adjustment for BMI.
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altered in CKD patients, leading to impairment in cholesterol
efflux [25]. Gluba-Brzozka et al. [12] found the same changes
in HDL subfractions and also proposed that large HDL may
have a unique proteome and lipid composition, associated
with an impaired cholesterol efflux capacity. This lack of
HDL functionality may contribute to the paradoxical coexis-
tence of increased large HDL and enhanced risk for CVD-
related events in ESRD patients.
In accordance with others [15, 26], we also found in
HD patients significantly higher levels of adiponectin (more
than twofold the control value), known for its beneficial
cardiovascular, antiatherogenic, anti-inflammatory, and anti-
diabetic properties. In obesity, type 2 DM, and coronary
artery disease, adiponectin levels appear to be reduced [27].
The adiponectin circulating levels are increased in HD
patients; however, it is still unclear if its effects on metabolism
remain intact. It has been hypothesized that the uremic
milieu, especially high in HD patients, may induce the devel-
opment of adiponectin resistance [28]. Another raised expla-
nation is that the enhanced adiponectin levels are due to a
decreased renal excretion, in ESRD [29]. It was also reported
that adiponectin may be secreted to alleviate inflammatory
or vascular injuries, although this counterregulation may not
be efficient enough, due to the effects of the proatherogenic
uremic environment [15].
We found that adiponectin correlated positively and
significantly with large HDL and negatively with intermedi-
ate and small HDL. Our data suggest that the enhancement
in adiponectin induces a more protective HDL profile, as
showed by the increase in large HDL and the decrease in
intermediate and small HDL particles. However, since HDLc
levels are low, these differences in HDL quality (size and
composition) may not produce a significant impact in CVD
risk, in HD patients. Besides, we cannot rule out the possibil-
ity that the alterations in size and composition are not
accompanied by improvement in HDL functionality.
Adiponectin is known to correlate inversely with adi-
posity, even in ESRD patients [16]. It was also reported
that in HD patients, adiponectin may have a role in improv-
ing oxidative stress that is common in these patients [30]. In
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Figure 2: Levels of oxidized low-density lipoprotein (oxLDL) (a), oxLDL/LDLc (b), adiponectin (c), and leptin (d), for end-stage renal disease
(ESRD) patients on chronic dialysis, according to the more prevalent comorbidities, diabetes mellitus (DM) and hypertension (HT). ∗P < 0 05;
∗∗P < 0 01; ∗∗∗P < 0 001; ″loss of significance after statistical adjustment for body mass index.
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agreement, we observed a significant inverse correlation
of adiponectin with oxLDL, oxLDL/LDLc, and BMI, in dial-
ysis patients. By performing a multiple linear regression
analysis, we found that the best predictors of adiponectin
levels were, besides BMI, large HDL and oxLDL/LDLc. It
appears that in ESRD patients on dialysis, adiposity and adi-
ponectin, large HDL, and LDL oxidation within LDL parti-
cles are tightly interrelated.
Concerning antioxidant properties of HDL, we found
that large HDL was significantly and inversely correlated
with oxLDL and oxLDL/LDLc, while intermediate and
small HDL subfractions were positively correlated with
oxidative changes in LDL, suggesting that HDL subfrac-
tions may have different roles in what concerns antioxi-
dant activity.
In the evaluation of LDL fractions and subfractions, we
found in dialysis patients, as compared to controls, signifi-
cantly lower (%) larger LDL (LDL 1 and 2) and similar (%)
small LDL particles. Our data are in accordance with other
reports [11–13] showing the same changes in HD patients
and proposing that small dense LDL particles are not associ-
ated with CVD in these patients [31].
CKD has been associated with hypertriglyceridemia,
impairment of VLDL catabolism, due to lipoprotein lipase
Table 3: Lipid profile, oxidized low-density lipoprotein (oxLDL), paraoxonase (PON) 1 activity, C-reactive protein (CRP), adipokines, and
fractions and subfractions of lipoproteins for end-stage renal disease (ESRD) patients on chronic dialysis, according to body mas index
(BMI) groups.
BMI < 18 5 kg/m2
(n = 8)
BMI 18 5–24.9 kg/m2
(n = 81)
BMI 25–29.9 kg/m2
(n = 60) BMI ≥ 30 kg/m
2 (n = 45)
Biochemical data
TC (mg/dl) 171 ± 28 162 ± 40 157 ± 40 159 ± 36
HDLc (mg/dl) 54.4 (53.1–83.1) 49.4a,∗ (41.8–59.8) 44.5aa (36.3–54.1)b,∗ 40.9aaa (34.8–48.7)bbb
LDLc (mg/dl) 62 (79–94) 77 (64–108) 79 (59–101) 80 (63–103)
TG (mg/dl) 111.5 (74.8–140.0) 116.0 (83.5–161.0) 134.5 (99.0–194.0)b,∗ 156.0a,∗ (114.0–237.0)bb,∗
TC/HDLc 2.96 (2.17–3.17) 3.13 (2.52–3.74) 3.24 (2.76–4.21) 3.96a∗ (3.03-4.26)bb,∗
LDLc/HDLc 1.39 (0.87–1.68) 1.71 (1.18–2.10) 1.71 (1.30–2.40) 2.01a,∗ (1.44–2.42)b,∗
oxLDL (U/l) 45.8 (29.2–52.2) 44.6 (36.1–55.8) 49.6 (35.3–62.9) 50.0 (41.5–63.7)b,∗
oxLDL/LDLc (U/mg) 0.052 (0.045–0.065) 0.047 (0.054–0.066) 0.052 (0.060–0.075)b,∗ 0.064 (0.051–0.076)b,∗
PON1 (nmol of
p-nitrophenol/ml/min)
379 (339–464) 393 (362–459) 423 (353–488) 399 (368–465)
PON1/HDLc 6.56 (4.11–8.79) 8.31 (6.38–10.35) 9.54a,∗ (7.69–11.20)b,∗ 9.99aa,∗ (8.68–12.13)bb
CRP (mg/dl) 0.44 (0.21–2.08) 0.32 (0.12–0.71) 0.36 (0.18–0.74) 0.42 (0.19–0.75)
Adiponectin (ug/ml) 28.65 (20.93–35.69) 16.24aa (9.73–23.56) 11.48aaa (7.25–16.20)bb,∗ 8.23aaa (5.43–12.78)bbb
Leptin (ng/ml) 3.40 (0.70–7.37) 6.50 (2.44–17.36) 17.42aa,∗ (6.96–49.19)bbb,∗ 43.08aaa (20.31–97.09)bbb,ccc
Lipoprotein fractions/subfractions
VLDL (%) 16 4 ± 2 2 17 6 ± 3 7 19 2a,∗ ± 4 1b,∗ 20 3aa,∗ ± 4 1bbb
MID-C (%) 15 2 ± 2 3 15 8 ± 2 3 16 6 ± 2 3 16 2 ± 2 0
MID-B (%) 6.9 (5.6–7.5) 7.8 (6.3–8.8) 7.9a,∗ (7.0–9.6) 7.7a,∗ (7.0-9.5)
MID-A (%) 6.2 (4.1–7.5) 6.6 (5.3–8.4) 6.9 (5.6–8.8) 6.9 (5.2–8.3)
LDL 1 (%) 12.3 (9.4–13.9) 13.4 (11.2–16.2) 13.0 (10.3–15.7) 12.8 (10.9–15.2)
LDL 2 (%) 7.2 (6.4–11.0) 8.2 (5.4–11.1) 7.8 (5.4–10.0) 8.4 (5.8–11.7)
LDL 3-7 (%) 1.2 (0.9–1.6) 0.0 (0.0–1.8) 0.7 (0.0–1.8) 0.8 (0.0–2.0)
HDL (%) 31.1 (29.6–38.2) 27.4 (24.2–32.3) 26.7a (22.7–29.9)bb 25.0aa (21.8–27.6)
LDL size 270 (269–270) 271 (268–272) 270 (268–273) 270 (267–272)
HDL subfractions
Large HDL (%) 43.8 (40.5–47.7) 40.7 (30.0–49.3) 36.6a,∗ (26.6–43.2)b,∗ 28.6a,∗ (24.7–37.9)bbb; c,∗
Intermediate HDL (%) 43.3 (39.8-45.3) 44.3 (39.8–48.2) 46.3 (40.7–50.0) 48.5a,∗ (44.5–50.5)bb,
Small HDL (%) 13.3 (11.0–16.7) 14.1 (10.6–21.0) 17.4 (13.5–22.4)b,∗ 21.2a,∗ (15.9–27.3)bbb; c,∗
TC: total cholesterol; HDLc: high-density lipoprotein cholesterol; TG: triglycerides; VLDL: very-low-density lipoprotein; MID: midbands (these comprise
intermediate-density lipoprotein (IDL)); LDL 3–7 corresponds to small LDL subfractions. Values are presented as median (interquartile range) or as
mean ± standard deviation (SD); aP < 0 05, aaP < 0 01, and aaaP < 0 001 vs. ESRD patients with BMI < 18 5 kg/m2; bP < 0 05, bbP < 0 01, and bbbP < 0 001
vs. ESRD patients with BMI 18.5–24.9 kg/m2; cP < 0 05, ccP < 0 01, and cccP < 0 001 vs. ESRD patients with BMI 24.9–29.9 kg/m2; ∗loss of significance
after statistical adjustment for diabetes.
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deficiency/dysfunction [32], and IDL has been reported as
an independent risk factor for atherosclerosis [33]. In
accordance, we observed higher values of TG, VLDL, and
IDL-B in ESRD patients. The lower HDLc levels in
ESRD, also observed in our patients, have been associated
with a decrease in apolipoprotein A-1 production and in
lecithin-cholesterol acyltransferase activity [34].
Diabetes and hypertension are common comorbidities in
HD patients and may contribute to the high CVD risk in
these patients. In that way, we analyzed our patients accord-
ing to the coexistence of such comorbidities.
We found that patients with DM presented a different
and less protective lipid profile than the other patients under
chronic dialysis. Patients with DM and DM+HT, as com-
pared to dialysis patients without DM, presented several sig-
nificant risk changes, namely, higher BMI scores, as well as
higher values of TG, oxLDL, oxLDL/LDLc, and leptin, and
lower HDLc, large HDL subfraction, and adiponectin. The
HD patients presenting only HT and the patients without
DM or HT showed a similar and more protective profile.
These findings suggest that these comorbidities (DM and
HT) contribute differently to CV risk profile. In accordance
with our data, Likely et al. [16] also reported lower adiponec-
tin values in diabetic ESRD patients, when compared with
nondiabetic patients, although higher than in controls. Con-
sidering that DM and DM+HT patients presented a signifi-
cantly higher BMI, as compared to the other two groups,
we performed a statistical adjustment for BMI; the differ-
ences in oxLDL, oxLDL/LDLc, and adiponectin between
diabetic and nondiabetic ESRD patients persisted signifi-
cantly (Figure 2). It is known that oxidative modifications
in LDL play a crucial role in the initiation and progression
of atherosclerosis [35] and are accepted as a marker for
CVD risk. The significant enhancement in LDL oxidation
in the diabetic patients, as well as the reduced values of
adiponectin, may contribute to the poor outcome [36]
and health-related quality of life [37] reported for diabetic
patients with ESRD.
In considering the importance of obesity as a predispos-
ing factor for diabetes and for CVD, we analyzed our data
according to BMI categories and, afterwards, performed a
statistical adjustment for diabetes. The obese patients pre-
sented the less protective CVD risk profile, with significantly
lower HDLc, % of large HDL, and adiponectin and signifi-
cantly higher (%) small HDLc subfractions and leptin. These
changes persisted significantly after adjustment for diabetes,
suggesting that in HD patients, the values of HDLc and HDL
subfractions are tightly related with adiposity.
High levels of leptin, associated with reduction in its
activity, are known to lead to severe insulin resistance [38].
Hyperleptinemia is also known to correlate with progression
of CKD [17]. Hypoadiponectinemia induces a decrease in
glucose uptake in the skeletal muscle, an increase in
hepatic gluconeogenesis, and a diminishment in fatty acid
oxidation favoring insulin resistance and type 2 DM [39].
Higher adiposity is known to associate with a decrease in
adiponectin and an increase in leptin levels [40, 41]. The
differences we found in adipokines levels suggest that in
ESRD patients under chronic dialysis, diabetes and higher
BMI associate with lower adiponectin and with an enhance-
ment in leptin levels. In spite of the higher CRP values in
ESRD patients, no correlations were found with the coexis-
tence of comorbidities and with BMI categories, suggesting
that inflammation is particularly linked to renal disease
and/or dialysis.
Statins, known to lower cholesterol and LDLc levels,
possess other effects, such as endothelial function improve-
ment and antioxidant and anti-inflammatory properties.
According to the literature, the effects of statin on HDL
subfractions are especially related with subfraction composi-
tion [42–44]; concerning the effect of statins on the size of
LDL subfractions, data is controversial [42, 45]. Nonetheless,
in our study, the number of diabetic, overweight, and obese
patients on statin therapy was higher than in the other groups
analyzed. Thus, the use of statins appears to have an irrele-
vant impact in the changes observed on the HDL subfrac-
tions and adipokine profile.
In summary, in ESRD patients, the higher adiponectin
levels seem to favor HDL modifications, from smaller to
larger subfractions, and antioxidant protection for LDL par-
ticles. ESRD diabetic patients presented higher values of
oxLDL, oxLDL/LDLc, and leptin and lower adiponectin than
nondiabetic patients; obese patients revealed lower HDLc
and adiponectin, higher leptin and a more atherogenic
HDL subfractions profile.
Our data suggest that the coexistence of DM and adipos-
ity in ESRD patients on dialysis contributes to a higher CVD
risk, as showed by their lipid and adipokine profiles.
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